We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to apply for marketing authorisation via this new procedure.
The MHRA accepts an Active Substance Master File and/or a Certificate of Suitability in both new national initial Marketing Authorisation Applications (MAA) and in Marketing Authorisation Variation (MAV) applications.
An overview of the legal requirements for children’s medicines that Marketing Authorisation Holders (MAHs) need to abide by.
The Medicines and Healthcare products Regulatory Agency (MHRA) offer a pre-submission service before applying for medicines Marketing Authorisations.
Supplementary information on the licensing of medicines for human use in the UK following the agreement of the Windsor Framework.
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
Guidance for holders of marketing authorisations (MAs) approved in Northern Ireland (NI) who want to bring a product to market in Great Britain (GB).
The approach the MHRA intends to take for products approved or pending in decentralised procedure (DCP) or mutual recognition procedures (MRP).
How manufacturers can apply for approval to supply a non-compliant medical device on humanitarian grounds.
How the MHRA makes decisions on whether a borderline product is a medical device and whether medical devices regulations should apply.
This guidance covers ‘grandfathering’ and managing the lifecycle changes of medicinal products.
How the MHRA makes decisions on whether a borderline product is a medical device or a medicinal product.
This guidance sets out how the MHRA is handling centralised applications that were still pending on 1 January 2021.
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
Supplementary information for international regulators on packaging changes and the export of UK medicines.
How and when to register updated packaging and information leaflets when new national marketing authorisations have been issued
Industry must notify the MHRA if they will not be using these flexibilities
Details of how Marketing Authorisation Holders can provide information on planned or potential future submissions, to the MHRA.
The UK government has introduced the Northern Ireland MHRA Authorised Route (NIMAR). This new route for supply became operational 1 January 2022.
Apply now to join the AI Airlock pilot by the MHRA. Benefit from industry and regulatory expert collaboration, bespoke testing plans, and improved regulatory understanding.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).